20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Tango Therapeutics Inc (TNGX) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 137 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, TNGX reported $62M in revenue and ($102M) in net income.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
Interactive charts & full statements → Open the TNGX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | $62M | $42M | $37M | $25M | $37M | $8M | $25M |
| Gross Profit | — | $60M | $42M | $37M | $25M | $37M | $6M | ($8M) |
| Gross Margin % | — | 96.3% | 100.0% | 100.0% | 100.0% | 100.0% | 78.8% | -30.9% |
| Operating Income (EBIT) | ($136M) | ($111M) | ($146M) | ($114M) | ($111M) | ($58M) | ($52M) | ($15M) |
| Operating Margin % | — | -178.4% | -346.1% | -312.6% | -446.8% | -157.1% | -681.8% | -61.5% |
| Net Income | ($124M) | ($102M) | ($130M) | ($102M) | ($108M) | ($58M) | ($52M) | ($14M) |
| Net Margin % | — | -162.8% | -309.7% | -278.5% | -435.1% | -157.2% | -678.8% | -57.2% |
| EBITDA | ($122M) | ($99M) | ($128M) | ($99M) | ($109M) | ($57M) | ($50M) | ($15M) |
| Earnings Per Share (EPS) | $-0.88 | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 | $-0.59 | $-0.16 |
| Shares Outstanding (M) | 150M | 116M | 109M | 95M | 88M | 62M | 87M | 87M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $54M | $3M | $5M | $4M | $12M |
| Gross Profit | — | $0M | $0M | $54M | $3M | $5M | $4M | $12M |
| Gross Margin % | — | — | — | 100.0% | 80.3% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($60M) | ($49M) | ($42M) | $14M | ($41M) | ($43M) | ($41M) | ($33M) |
| Operating Margin % | — | — | — | 26.2% | -1287.9% | -788.8% | -993.7% | -283.3% |
| Net Income | ($55M) | ($46M) | ($39M) | $16M | ($39M) | ($40M) | ($38M) | ($29M) |
| Net Margin % | — | — | — | 29.5% | -1221.4% | -739.5% | -915.0% | -251.3% |
| EBITDA | ($55M) | ($45M) | ($38M) | $16M | ($38M) | ($39M) | ($37M) | ($28M) |
| Earnings Per Share (EPS) | $-0.37 | $-0.32 | $-0.33 | $0.14 | $-0.35 | $-0.36 | $-0.35 | $-0.27 |
| Shares Outstanding (M) | 150M | 144M | 116M | 111M | 111M | 110M | 109M | 109M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($144M) | ($139M) | ($132M) | ($118M) | ($109M) | ($60M) | $70M | ($25M) |
| Capital Expenditures (CapEx) | $0M | $1M | $1M | $2M | $8M | $2M | $1M | $2M |
| Free Cash Flow (FCF) | ($144M) | ($140M) | ($132M) | ($120M) | ($117M) | ($61M) | $69M | ($27M) |
| FCF Margin % | — | -224.3% | -314.4% | -327.2% | -469.7% | -165.7% | 900.8% | -108.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($39M) | ($44M) | ($30M) | ($31M) | ($37M) | ($42M) | ($37M) | ($33M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $1M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($39M) | ($44M) | ($30M) | ($31M) | ($37M) | ($42M) | ($37M) | ($34M) |
| FCF Margin % | — | — | — | -57.8% | -1167.7% | -774.3% | -893.1% | -288.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1B | $399M | $316M | $403M | $436M | $500M | $207M | $56M |
| Cash & Cash Equivalents | $346M | $112M | $70M | $66M | $60M | $143M | $28M | $23M |
| Total Liabilities | $49M | $53M | $117M | $149M | $187M | $155M | $169M | $48M |
| Total Debt (Short + Long-Term) | $3M | $3M | $2M | $2M | $2M | $2M | $1M | $1M |
| Total Shareholders' Equity | $1.0B | $346M | $200M | $253M | $249M | $345M | $39M | $8M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TNGX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms